ClinicalTrials.gg
RecruitingNCT06347315Updated Jun 18, 2026

Evaluation of the Effects of a Nutritional Intervention of Ketogenic Medium-chain Triglycerides and B-vitamins on Cognitive Functioning in Older Adults With Mild Cognitive Impairment (COGNIKET-MCI)

An interventional study of BrainXpert and Placebo in Mild Cognitive Impairment, sponsored by Société des Produits Nestlé (SPN). Recruiting at 28 sites in 6 countries. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-06-18.

Sponsored by Société des Produits Nestlé (SPN) (part of Nestlé S.A.) · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started May 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
380
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 175 studies in Cognitive Dysfunction with a site in Italy — 74 open to participants now, 87 under way, 6 of them phase 3. Cognitive Dysfunction · Italy.

Planned enrollment
17th of 111
380 · median 80
Started
2024
with 29 others
No phase
93 of 175
42 open now
Primary completion
2027-12
later than 66 of 86 live
Registered
100th of 175
by date

Among the 175 studies in Cognitive Dysfunction with a site in Italy, this one is the 17th largest by planned enrollment of the 111 interventional ones that give a count, is one of 30 that started in 2024, is one of 93 with no phase, reaches primary completion later than 66 of the 86 other live ones, and was the 100th registered.

Cognitive Dysfunction

3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

74 of the 175 studies in Cognitive Dysfunction with a site in Italy are open now. Recruiting first, the newest first:

69 more — sign in →

All 74 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 175 studies in Cognitive Dysfunction with a site in Italy, or all of them as a file.
02

Study summary

Evaluation of the Effects of a Nutritional Intervention of Ketogenic Medium-chain Triglycerides and B-vitamins on Cognitive Functioning in Older Adults With Mild Cognitive Impairment (COGNIKET-MCI)

03

Conditions studied

  • Mild Cognitive Impairment
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have read, understood, and signed the form (ICF).
  2. Be aged ≥60 years at the time of screening.
  3. Presence of acquired memory complaints with a duration of >3 months. Here we refer to memory/cognitive complaints in a broader sense that can involve other cognitive domains other than memory. (As reported by the participant or reliable trial informant. Trial informants can be a relative, spouse or domestic partner, or close friend who interacts closely enough with the participant to be able to respond to assessments/questionnaires as needed.)
  4. Have a clinical diagnosis of MCI (with a clinical phenotype compatible with AD, insidious SVD [ie, no post-stroke cognitive impairment], or mixed AD/SVD) according to the participating site, or referring center, aligned with international/national standards for MCI diagnosis, and additionally informed by a minimum of one of the following objective criteria as assessed by components of the Consortium to Establish a Registry for Alzheimer's Disease neuropsychological battery (CERAD NB):

    1. Word list memory task: ≤19,
    2. Word list recall: ≤5,
    3. Fifteen-item subset of the Boston Naming Test (BNT): ≤13,
    4. Constructional praxis recall: ≤7, or
    5. Total CERAD score: ≤70.
  5. Full autonomy for daily living based on the Instrumental Activities of Daily Living (IADL)-Lawton scale:

    1. Score for women: 8 or
    2. Score for men: 5.
  6. Participants must have an available trial informant willing and able to attend the following 3 clinic visits with the participant: V1/randomization, V3/12-month visit, and V4/18-month visit.
  7. Participants must have a trial informant who in the opinion of the investigator, has contact with the trial participant for a sufficient number of hours per week (at least 2 hours per day and a minimum of 4 times per week).
  8. Participants and their trial informants have an adequate ability to read and write, as well as adequate vision and hearing for neuropsychological testing according to the investigator's judgment (corrective aids are allowed).
  9. CDR global score of 0 to 0.5 at screening.
  10. Sexually active females of (defined in further detail in Appendix 1 of the protocol) must practice 2 different highly effective methods of with their heterosexual partner or remain abstinent during the trial and for 30 days after the last dose of nutritional formulation. If employing contraception, the highly effective methods of contraception detailed in Appendix 1 of the protocol must be followed.
  11. Females of childbearing potential must have a negative highly sensitive urine pregnancy test before randomization; a positive urine pregnancy test result must immediately be confirmed using a serum test.
  12. Participants able to satisfactorily comply with the protocol requirements.
  13. Participants willing and able to discontinue all prohibited concomitant medications to meet any protocol-required before and during the trial period (Section 9.6.1 of the protocol provides more details).

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of a major neurocognitive disorder according to the 5th Edition of the (DSM-5), or dementia according to the DSM-IV and the National Institute of Neurological and Communicative Diseases and Stroke/Alzheimer's Disease and Related Disorders Association criteria at the time of enrollment.
  2. MCI related to past or recent concussion, COVID-19, or other specific etiologies (including neurodegenerative disease like Parkinson's disease, multiple sclerosis, Huntington's disease, Lewy-body disease, fronto temporal dementia), or associated with medication/substance use, per the investigator's judgment.
  3. A history of COVID-19 ≤120 days before screening or completion of a vaccination course against severe acute respiratory syndrome coronavirus 2 ≤14 days before screening. The vaccine received must have been authorized for emergency use or approved by the US Food and Drug Administration.
  4. Newly introduced, or change in dose, within the last 2 months before randomization, of physician-prescribed interventions or medications affecting cognition or AD (eg, acetylcholinesterase inhibitors, memantine, anti-amyloid-beta agents), or planned introduction of such medications during the trial.
  5. Participants who will likely require prohibited concomitant therapy during the trial based on the investigator's judgment.
  6. Known history of or ongoing alcohol or substance use disorder, based on medical history, that in the opinion of the investigator may conflict with the participant's participation.
  7. Participants who, in the opinion of the investigator, medical monitor, or sponsor should not participate in the trial.
  8. Symptoms suggestive of depression or anxiety according to the Hospital Anxiety and Depression Scale (HADS):

    1. HADS-D ≥8 or
    2. HADS-A ≥8.
  9. Known active infection, COVID, , or based on medical history.
  10. Participants with epilepsy or a history of seizures, except for a single childhood febrile seizure, post-traumatic seizure, or alcohol withdrawal seizure.
  11. Participants considered to be in poor general health based on the investigator's judgment. Examples include participants who have recent weight loss, chronic dehydration or hypovolemia, poor fluid or nutritional intake, or a recent clinically significant infection, as per the investigator's judgment.
  12. Cancer diagnosis in the past 2 years excluding select skin conditions considered to be fully treated (basal cell or squamous cell carcinomas of the skin) or early-stage cancer with excellent prognosis (eg, some prostate cancer conditions) according to the investigator's judgment.
  13. Renal disease (estimated \<30 ml/min/1.73m2) based on the investigator's assessment and historical data.
  14. Uncontrolled hypertension (systolic blood pressure >160 mm Hg, and/or diastolic blood pressure >100 mm Hg).
  15. Significant and uncontrolled thyroid disease according to the investigator's judgment.
  16. Any surgery or procedure requiring general anesthesia ≥3 hours, planned, or in the previous 3 months.
  17. Poorly regulated type 2 diabetes ( >9.0%), or type 2 diabetes that is currently treated with insulin, glucagon-like peptide-1 receptor analog (GLP-1 RA), or a sodium-glucose cotransporter-2 (SGLT-2) inhibitor, or type 1 diabetes.
  18. Vitamin B12 deficiency per the investigator's judgment, or current use of B-vitamin supplementation >200% daily recommended value according to national standards.
  19. Very high or severe hypertriglyceridemia (≥886 mg/dL or 10.0 mmol/L).
  20. Participants who are unable to comply with protocol procedures in the opinion of the investigator (if an individual develops a major neurocognitive disorder during the course of the trial, the appropriateness for the individual to continue will be based on the investigator's judgment).
  21. Have a personal or hierarchical link with the research team members.
  22. Participant who is a shift worker that involves night shifts.
  23. Ongoing/planned pregnancy or breastfeeding at screening (female participants who have a positive pregnancy test result before receiving nutritional formulation will be excluded).
  24. Participants who follow a ketogenic diet or other diet that is intended to influence ketone levels (eg, prolonged fasting, intermittent fasting, ketogenic meal replacement product regimens), or take ketone-, kMCT-, or coconut oil supplementation, or adhere to a diet that excludes milk product use (eg, vegan diet).
  25. Cow's milk protein allergy or intolerance, or other allergy or intolerance to any of the ingredients of the nutritional formulation (eg, medium chain acyl-CoA deficiency, or other fatty acid oxidation disorders).

US protocol specificities:

4. Have MCI (with a clinical phenotype compatible with AD, insidious SVD [ie, no post-stroke cognitive impairment], or mixed AD/SVD) according to the participating site or referring center, as aligned with the National Institute on Aging and the Alzheimer's Association or Mayo Clinic standards for MCI, and additionally informed by a minimum of one of the following objective criteria as assessed by components of the Consortium to Establish a Registry for Alzheimer's Disease neuropsychological battery (CERADNB):

  1. Word list memory task: ≤19,
  2. Word list recall: ≤5,
  3. Fifteen-item subset of the Boston Naming Test (BNT): ≤13,
  4. Constructional praxis recall: ≤7, or
  5. Total CERAD score: ≤70.

    6. Participants must have an available trial informant willing to attend the following 4 clinic visits with the participant: screening, V1/randomization, V3/12-month visit, and V4/18-month visit.

    9. CDR global score of 0 at screening.

    10. Sexually active females of must practice highly effective methods of with their heterosexual partner (defined in further detail in Appendix 1 of the protocol) or remain abstinent during the trial and for 30 days after the last dose of nutritional formulation. If employing contraception, the highly effective methods of contraception detailed in Appendix 1 of the protocol must be followed.

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
380 participants (estimated)

Study arms

  • Active comparator
    BrainXpert

    15 g kMCT + B-vitamins (B3, B6, B9/folic acid, and B12) will be provided in powder format

    Dietary Supplement: BrainXpert

  • Placebo comparator
    Placebo

    high-oleic acid sunflower oil as a calorie-equivalent, non-ketogenic vegetable oil, non added vitamin product will be provided in a powder format .

    Other: Placebo

Interventions

  • Dietary supplementBrainXpert

    sachet/stickpack of 25 g, has no preservatives, no flavors, no sweeteners, and no colorants.

  • OtherPlacebo

    high-oleic acid sunflower oil as a calorie-equivalent, non-ketogenic vegetable oil, non added vitamin product will also be provided in a powder format in a sachet/stickpack of 25 g.

06

What researchers measure

Primary outcomes

  1. Preclinical Alzheimer's Cognitive Composite (PACC) score

    The change from baseline on the PACC composite cognitive score of episodic memory, timed executive function, and global cognition PACC has 4 components: * Free and Cued Selective Reminding Test (0 (worst)-96 (best recall); * Logical Memory Ib (Immediate Recall) from the WMS-IV (Range 0 (worst)-25 (best recall); * Wechsler Adult Intelligence scale - revised: Digit Symbol Substitution Test (DSST): (ranges 0 \[none\]-93 \[best performance\]) * Mini Mental State Examination (Range 0 \[worst\] - 30 \[best performance\]). Component scores are transformed using an established normalization method into z-scores. Each of 4 component change scores is divided by baseline sample standard deviation (SD) of that component. These z scores are summed to form the composite score. A z-score of 0 is equal to the mean and implies how many SD higher or lower score as compared with baseline score, with increase signifying improvement.

    Time frame: 12 months

Secondary outcomes

  1. Preclinical Alzheimer's Cognitive Composite (PACC) (components effects)

    Individual interventional effects on change from baseline in the individual components of the PACC test (cognitive domains of executive function, episodic memory, and global cognitive function) PACC has 4 components: * Free and Cued Selective Reminding Test (0 (worst)-96 (best recall); * Logical Memory Ib (Immediate Recall) from the WMS-IV (Range 0 (worst)-25 (best recall); * Wechsler Adult Intelligence scale - revised: Digit Symbol Substitution Test (DSST): (ranges 0 \[none\]-93 \[best performance\]) * Mini Mental State Examination (Range 0 \[worst\] - 30 \[best performance\]).

    Time frame: 12 months

  2. Montreal Cognitive Assessment (MoCA) score

    The change from baseline in the Montreal Cognitive Assessment (MoCA) total score Scale range 0 to 30 - higher score indicates better performance

    Time frame: 12 months

  3. Preclinical Alzheimer's Cognitive Composite (PACC) accelerated decline

    Percentage of participants achieving accelerated cognitive decline, defined as a change from baseline in the PACC z-score of at least 1 SD below the mean PACC has 4 components: * Free and Cued Selective Reminding Test (0 (worst)-96 (best recall); * Logical Memory Ib (Immediate Recall) from the WMS-IV (Range 0 (worst)-25 (best recall); * Wechsler Adult Intelligence scale - revised: Digit Symbol Substitution Test (DSST): (ranges 0 \[none\]-93 \[best performance\]) * Mini Mental State Examination (Range 0 \[worst\] - 30 \[best performance\]). Component scores are transformed using an established normalization method into z-scores. Each of 4 component change scores is divided by baseline sample standard deviation (SD) of that component. These z scores are summed to form the composite score. A z-score of 0 is equal to the mean and implies how many SD higher or lower score as compared with baseline score, with increase signifying improvement.

    Time frame: 12 months

  4. Wechsler Memory Scale - Fourth Edition (WMS-IV) Logical Memory IIb Delayed Recall Score accelerated decline

    Percentage of participants achieving accelerated memory decline, defined as a change from baseline in episodic memory (\>3 points) as assessed by the "WMS-IV Logical Memory IIb Delayed Recall Score" Wechsler Adult Intelligence scale: Digit Symbol Substitution Test (DSST): (ranges 0 \[none\]-91 \[best performance\])

    Time frame: 12 months

  5. Mini-Mental State Examination (MMSE) score accelerated decline

    Percentage of participants achieving accelerated cognitive decline, defined as a change from baseline in the Mini-Mental State Examination (MMSE) total score of \<24 or a decline of \>3 points Scale range 0 to 30 - higher score indicates better performance

    Time frame: 12 months

  6. Emergent Adverse Events (Safety and tolerability)

    Adverse events (AEs), including gastrointestinal tolerability and nausea, vital signs, changes in blood biomarkers (hematology, liver, kidney) over the course of the trial

    Time frame: 12 months

07

Study locations

28 of 28 sites recruiting
  • Hôpital Pierre Wertheimer
    Bron, France
    Recruiting
    • Helene Mollion, MD · Contact
  • CHU de Montpellier - Hôpital Gui de Chauliac
    Montpellier, France
    Recruiting
    • Karim Bennys, MD · Contact
  • CHU de Nantes - Hôpital Nord Laennec
    Nantes, France
    Recruiting
    • Claire Boutoleau-Bretonniere, MD · Contact
  • CHU de Toulouse - Gerontopole
    Toulouse, France
    Recruiting
    • Pierre Jean Ousset, MD · Contact
  • Klinikum Bayreuth GmbH - Klinik Hohe Warte
    Bayreuth, Germany
    Recruiting
    • Patrick Oschmann, MD · Contact
  • Studienzentrum für Neurologie und Psychiatrie
    Böblingen, Germany
    Recruiting
    • Felix Bischof, MD · Contact
  • Neuro Centrum Science GmbH
    Erbach im Odenwald, Germany
    Recruiting
    • Gerd Reifschneider, MD · Contact
  • Universitaetsmedizin Ulm
    Ulm, Germany
    Recruiting
    • Doerte Polivka, MD · Contact
  • Foundation Institute G.Giglio
    Cefalù, Italy
    Recruiting
    • Luigi Grimaldi, MD · Contact
  • IRCCS Ospedale Policlinico San Martino
    Genova, Italy
    Recruiting
    • Matteo Pardini, MD · Contact
  • Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone"
    Palermo, Italy
    Recruiting
    • Mario Barbagallo, MD · Contact
  • AOU Policlinico Umberto I - Sapienza Università di Roma
    Roma, Italy
    Recruiting
    • Giuseppe Bruno, MD · Contact
  • Azienda Ospedaliera SantAndrea
    Roma, Italy
    Recruiting
    • Franco Giubilei, MD · Contact
  • Laboratory of Neuropsyichiatry, Fondazione Santa Lucia IRCCS
    Roma, Italy
    Recruiting
    • Clelia Pellicano, MD · Contact
  • Policlinico Universitario Agostino Gemelli
    Roma, Italy
    Recruiting
    • Camillo Marra, MD · Contact
  • AO Card. G. Panico
    Tricase, Italy
    Recruiting
    • Daniele Urso, MD · Contact
  • Hospital Universitario del Vinalopó
    Alicante, Spain
    Recruiting
    • Ana López García, MD · Contact
  • Fundaciò ACE
    Barcelona, Spain
    Recruiting
    • Merce Boada Rovira, MD · Contact
  • HGU Gregorio Marañón
    Madrid, Spain
    Recruiting
    • Javier Olazarán, MD · Contact
  • Unidad de Investigación Neurociencias Centro de Salud San Juan
    Salamanca, Spain
    Recruiting
    • Angel Luis Montejo Gonzalez, MD · Contact
  • Hospital Universitari General de Catalunya
    Sant Cugat del Vallès, Spain
    Recruiting
    • Ernest Balaguer Martinez, MD · Contact
  • Hospital Universitario Victoria Eugenia
    Seville, Spain
    Recruiting
    • Felix Vinuela Fernandez, MD · Contact
  • Hospital Universitari i Politecnic La Fe
    Valencia, Spain
    Recruiting
    • Miguel Baquero, MD · Contact
  • Universitare Altersmedizin FELIX PLATTER
    Basel, Basel 4055, Switzerland
    Recruiting
  • Spitalzentrum Centre Hospitalier Biel-Bienne AG (SZB)
    Biel, Switzerland
    Recruiting
    • Hans-Albert Pihan, MD · Contact
  • CHUV
    Lausanne, Switzerland
    Recruiting
    • Olivier Rouaud, MD · Contact
  • Sussex Partnership NHS foundation Trust
    Crowborough, United Kingdom
    Recruiting
    • Naji Tabet, MD · Contact
  • Hampshire & Isle of Wight Healthcare NHS Foundation Trust
    Southampton, United Kingdom
    Recruiting
    • Brady McFarlane, MD · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Dec 2027, 42 months after the start.

Of 69 industry-sponsored interventional studies with no phase under Cognitive Dysfunction, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 35. This study's planned 42 months is above that.

Counting every sponsor, half of 1,522 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2024
First posted
Apr 4, 2024
StartActual
May 24, 2024
Primary completionEst.
Dec 15, 2027
CompletionEst.
Dec 15, 2027
Last update
Jun 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06347315
Collaborators
Syneos Health
Responsible party
Sponsor
First posted
Apr 4, 2024
Start date
May 24, 2024
Primary completion
Dec 15, 2027 (estimated)
Completion
Dec 15, 2027 (estimated)
Last update
Jun 18, 2026

Study contacts

Liljana Claret-Tournier
Contact
liljana.claret-tournier@rd.nestle.com
+41 21 924 9825

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion